Actively Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Led by AstraZeneca · Updated on 2026-04-21
161
Participants Needed
33
Research Sites
274 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
CONDITIONS
Official Title
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adequate performance status (ECOG for adults or Karnofsky/Lansky for adolescents)
- Adequate organ and bone marrow function
- For Module 1 Cohort 1 Part A: Age 18 years or older at consent
- For Module 1 Cohort 1 Part B: Age 12 years or older and weight at least 40 kg
- Histologically confirmed classical Hodgkin lymphoma (cHL) based on WHO criteria
- For Cohort 1: At least 2 prior lines of therapy including brentuximab vedotin and anti-PD1, with relapsed/refractory active disease
- For Cohort 2: Age 50 years or older, advanced stage (III/IV) cHL, at least 4 cycles of frontline standard therapy with partial or complete response
- For Cohort 3: Age 18 years or older, histologically confirmed peripheral T-cell lymphoma (PTCL NOS, ALCL, or AITL), at least 1 prior therapy with exhausted options, ALCL patients must have prior brentuximab vedotin treatment
- At least 1 measurable and/or FDG-avid lymphoma lesion (nodal >1.5 cm, extranodal >1 cm)
- Ability to provide formalin-fixed paraffin-embedded baseline tumor tissue
- For Cohort 3: Ability to provide on-treatment biopsy if tumor suitable
- For Module 2 Cohort 1: Age 18 years or older, histologically confirmed cHL, at least 1 prior therapy with relapsed/refractory active disease, measurable/FDG-avid lesion, and baseline tumor tissue
You will not qualify if you...
- Any significant lab abnormality or severe uncontrolled medical condition
- Active central nervous system lymphoma involvement or spinal cord compression
- Active hepatitis B or C infection
- Known HIV positive status
- Active gastrointestinal disease interfering with oral therapy
- ECG abnormalities including QTcF >470 msec or arrhythmia risks
- Recent major cardiac procedures or events within 6 months
- Severe valvular heart disease or congestive heart failure Grade II-IV
- Prior or current cardiomyopathy or uncontrolled hypertension
- Recent significant bleeding or hemoptysis within 4 weeks
- Unresolved toxicities greater than Grade 1 from prior cancer therapy (except some exceptions)
- History of other primary cancers
- Recent anti-lymphoma therapy within 21 days, radiation within 28 days, stem cell transplant within specified periods
- Need for ongoing immunosuppressive therapy including systemic corticosteroids
- For Module 2 Cohort 1: History of interstitial lung disease, severe immune-related adverse events from prior checkpoint inhibitors, autoimmune disorders, refractory to checkpoint inhibitors within 12 weeks, eligibility for stem cell transplant, recent allogeneic stem cell transplant with active graft-vs-host disease, and hypersensitivity to pembrolizumab or excipients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 33 locations
1
Research Site
Duarte, California, United States, 91010
Not Yet Recruiting
2
Research Site
Miami, Florida, United States, 33136
Actively Recruiting
3
Research Site
Atlanta, Georgia, United States, 30322
Withdrawn
4
Research Site
Boston, Massachusetts, United States, 02215
Actively Recruiting
5
Research Site
New York, New York, United States, 10016
Not Yet Recruiting
6
Research Site
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
7
Research Site
Houston, Texas, United States, 77030
Actively Recruiting
8
Research Site
Adelaide, Australia, 5000
Withdrawn
9
Research Site
Fitzroy, Australia, 3065
Not Yet Recruiting
10
Research Site
Nedlands, Australia, 6009
Actively Recruiting
11
Research Site
South Brisbane, Australia, 4101
Withdrawn
12
Research Site
Waratah, Australia, 2298
Withdrawn
13
Research Site
Beijing, China, 100191
Not Yet Recruiting
14
Research Site
Guangzhou, China, 510060
Not Yet Recruiting
15
Research Site
Shanghai, China, 20032
Not Yet Recruiting
16
Research Site
Créteil, France, 94010
Terminated
17
Research Site
Lille, France, 59000
Actively Recruiting
18
Research Site
Pierre-Bénite, France, 69310
Actively Recruiting
19
Research Site
Villejuif, France, 94805
Actively Recruiting
20
Research Site
Berlin, Germany, 12203
Not Yet Recruiting
21
Research Site
Cologne, Germany, 50937
Actively Recruiting
22
Research Site
Erlangen, Germany, 91054
Not Yet Recruiting
23
Research Site
Würzburg, Germany, 97080
Not Yet Recruiting
24
Research Site
Alessandria, Italy, 15100
Actively Recruiting
25
Research Site
Bologna, Italy, 40138
Actively Recruiting
26
Research Site
Milan, Italy, 20141
Actively Recruiting
27
Research Site
Kōtoku, Japan, 135-8550
Not Yet Recruiting
28
Research Site
Seoul, South Korea, 03080
Actively Recruiting
29
Research Site
Seoul, South Korea, 06351
Actively Recruiting
30
Research Site
L'Hospitalet de Llobregat, Spain, 08908
Actively Recruiting
31
Research Site
Madrid, Spain, 28041
Actively Recruiting
32
Research Site
Manchester, United Kingdom, M20 4BX
Actively Recruiting
33
Research Site
Oxford, United Kingdom, OX3 7LE
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here